JP2009005695A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009005695A5 JP2009005695A5 JP2008149091A JP2008149091A JP2009005695A5 JP 2009005695 A5 JP2009005695 A5 JP 2009005695A5 JP 2008149091 A JP2008149091 A JP 2008149091A JP 2008149091 A JP2008149091 A JP 2008149091A JP 2009005695 A5 JP2009005695 A5 JP 2009005695A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding portion
- monoclonal antibody
- antibody
- madcam
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 36
- 108091007433 antigens Proteins 0.000 claims 36
- 102000036639 antigens Human genes 0.000 claims 36
- 239000000203 mixture Substances 0.000 claims 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims 13
- 208000027866 inflammatory disease Diseases 0.000 claims 12
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 230000002401 inhibitory effect Effects 0.000 claims 8
- 210000000265 leukocyte Anatomy 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 7
- 230000009261 transgenic effect Effects 0.000 claims 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims 4
- 208000011231 Crohn disease Diseases 0.000 claims 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 4
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 210000004408 hybridoma Anatomy 0.000 claims 3
- 210000004698 lymphocyte Anatomy 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 2
- 208000012258 Diverticular disease Diseases 0.000 claims 2
- 206010013554 Diverticulum Diseases 0.000 claims 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 claims 2
- 208000007882 Gastritis Diseases 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000034189 Sclerosis Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 238000007792 addition Methods 0.000 claims 2
- 210000000941 bile Anatomy 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 229940027941 immunoglobulin g Drugs 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 claims 1
- 101150109698 A2 gene Proteins 0.000 claims 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 238000009007 Diagnostic Kit Methods 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
- 229940113720 aminosalicylate Drugs 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 1
- 229960002170 azathioprine Drugs 0.000 claims 1
- 230000021164 cell adhesion Effects 0.000 claims 1
- 102000008395 cell adhesion mediator activity proteins Human genes 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000009545 invasion Effects 0.000 claims 1
- 210000003563 lymphoid tissue Anatomy 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 230000007115 recruitment Effects 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53549004P | 2004-01-09 | 2004-01-09 | |
| US60/535,490 | 2004-01-09 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006549399A Division JP4315982B2 (ja) | 2004-01-09 | 2005-01-07 | ＭＡｄＣＡＭに対する抗体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009260786A Division JP5094818B2 (ja) | 2004-01-09 | 2009-11-16 | ＭＡｄＣＡＭに対する抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009005695A JP2009005695A (ja) | 2009-01-15 |
| JP2009005695A5 true JP2009005695A5 (cg-RX-API-DMAC7.html) | 2009-04-23 |
| JP4729076B2 JP4729076B2 (ja) | 2011-07-20 |
Family
ID=34794356
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006549399A Expired - Lifetime JP4315982B2 (ja) | 2004-01-09 | 2005-01-07 | ＭＡｄＣＡＭに対する抗体 |
| JP2008149091A Expired - Lifetime JP4729076B2 (ja) | 2004-01-09 | 2008-06-06 | ＭＡｄＣＡＭに対する抗体 |
| JP2009260786A Expired - Lifetime JP5094818B2 (ja) | 2004-01-09 | 2009-11-16 | ＭＡｄＣＡＭに対する抗体 |
| JP2012154794A Expired - Lifetime JP5836896B2 (ja) | 2004-01-09 | 2012-07-10 | ＭＡｄＣＡＭに対する抗体 |
| JP2015138764A Expired - Lifetime JP6215875B2 (ja) | 2004-01-09 | 2015-07-10 | ＭＡｄＣＡＭに対する抗体 |
| JP2017004899A Expired - Lifetime JP6423024B2 (ja) | 2004-01-09 | 2017-01-16 | ＭＡｄＣＡＭに対する抗体 |
| JP2018087973A Expired - Lifetime JP6637104B2 (ja) | 2004-01-09 | 2018-05-01 | ＭＡｄＣＡＭに対する抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006549399A Expired - Lifetime JP4315982B2 (ja) | 2004-01-09 | 2005-01-07 | ＭＡｄＣＡＭに対する抗体 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009260786A Expired - Lifetime JP5094818B2 (ja) | 2004-01-09 | 2009-11-16 | ＭＡｄＣＡＭに対する抗体 |
| JP2012154794A Expired - Lifetime JP5836896B2 (ja) | 2004-01-09 | 2012-07-10 | ＭＡｄＣＡＭに対する抗体 |
| JP2015138764A Expired - Lifetime JP6215875B2 (ja) | 2004-01-09 | 2015-07-10 | ＭＡｄＣＡＭに対する抗体 |
| JP2017004899A Expired - Lifetime JP6423024B2 (ja) | 2004-01-09 | 2017-01-16 | ＭＡｄＣＡＭに対する抗体 |
| JP2018087973A Expired - Lifetime JP6637104B2 (ja) | 2004-01-09 | 2018-05-01 | ＭＡｄＣＡＭに対する抗体 |
Country Status (37)
Families Citing this family (131)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2344592T3 (es) * | 2001-01-05 | 2010-09-01 | Pfizer Inc. | Anticuerpos frente al receptor del factor de crecimiento similar a la insulina i. |
| US7658924B2 (en) * | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| KR20050109489A (ko) * | 2003-02-13 | 2005-11-21 | 화이자 프로덕츠 인크. | 항-인슐린양 성장인자 ｉ 수용체 항체의 용도 |
| ES2427641T3 (es) | 2003-05-22 | 2013-10-31 | Ibio, Inc. | Molécula vehículo recombinante para la expresión, el suministro y la purificación de polipéptidos diana |
| PL2177537T3 (pl) * | 2004-01-09 | 2012-06-29 | Pfizer | Przeciwciała przeciw MadCAM |
| ES2690079T3 (es) | 2004-09-03 | 2018-11-19 | Genentech, Inc. | Antagonistas anti-beta7 humanizados y utilizaciones para los mismos |
| AR054233A1 (es) * | 2005-03-08 | 2007-06-13 | Pharmacia & Upjohn Co Llc | Composiciones de anticuerpos igg2 |
| JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
| DE602006017373D1 (de) * | 2005-07-08 | 2010-11-18 | Pfizer Ltd | Madcam-antikörper |
| WO2007007160A2 (en) * | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat fever |
| WO2007007151A2 (en) * | 2005-07-11 | 2007-01-18 | Pfizer Limited | Use of anti-mad-cam antibody for the treatment of emphysema |
| CA2614622A1 (en) * | 2005-07-11 | 2007-01-18 | Pfizer Limited | New combination of anti-madcam antibody and antifibrotic caspase inhibitor to treat liver fibrosis |
| KR101446025B1 (ko) | 2005-08-03 | 2014-10-01 | 아이바이오, 인크. | 면역글로불린의 생산을 위한 조성물 및 방법 |
| EP4218801A3 (en) | 2006-03-31 | 2023-08-23 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
| CA2647846C (en) | 2006-03-31 | 2016-06-21 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| US7745584B2 (en) * | 2006-05-22 | 2010-06-29 | California Institute Of Technology | Antibodies to sulfated carbohydrates |
| EP1878747A1 (en) * | 2006-07-11 | 2008-01-16 | greenovation Biotech GmbH | Glyco-engineered antibodies |
| WO2008033159A1 (en) * | 2006-09-15 | 2008-03-20 | Fraunhofer Usa, Inc. | Influenza antibodies, compositions, and related methods |
| AU2008262490B2 (en) | 2007-05-22 | 2011-11-17 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
| WO2009009759A2 (en) | 2007-07-11 | 2009-01-15 | Fraunhofer Usa, Inc. | Yersinia pestis antigens, vaccine compositions, and related methods |
| PL2202245T3 (pl) | 2007-09-26 | 2017-02-28 | Chugai Seiyaku Kabushiki Kaisha | Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr |
| WO2009041613A1 (ja) | 2007-09-26 | 2009-04-02 | Chugai Seiyaku Kabushiki Kaisha | 抗体定常領域改変体 |
| US8912149B1 (en) | 2007-11-28 | 2014-12-16 | California Institute Of Technology | Glycosaminoglycan mimetics |
| KR20160074019A (ko) | 2007-12-05 | 2016-06-27 | 추가이 세이야쿠 가부시키가이샤 | 항ｎｒ１０ 항체 및 그의 이용 |
| JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
| ES2533480T3 (es) * | 2008-05-16 | 2015-04-10 | F. Hoffmann-La Roche Ag | Uso de biomarcadores para evaluar el tratamiento de trastornos inflamatorios gastrointestinales con antagonistas de la integrina beta7 |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| WO2010037046A1 (en) | 2008-09-28 | 2010-04-01 | Fraunhofer Usa, Inc. | Humanized neuraminidase antibody and methods of use thereof |
| US9228017B2 (en) | 2009-03-19 | 2016-01-05 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| US20120071634A1 (en) | 2009-03-19 | 2012-03-22 | Chugai Seiyaku Kabushiki Kaisha | Antibody Constant Region Variant |
| CN103382222B (zh) * | 2009-03-20 | 2016-12-28 | 安姆根有限公司 | α-4-β-7异二聚体特异性拮抗剂抗体 |
| CA3018235C (en) | 2009-03-20 | 2021-01-12 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
| WO2010131733A1 (ja) | 2009-05-15 | 2010-11-18 | 中外製薬株式会社 | 抗axl抗体 |
| WO2011037158A1 (ja) | 2009-09-24 | 2011-03-31 | 中外製薬株式会社 | 抗体定常領域改変体 |
| US8784819B2 (en) | 2009-09-29 | 2014-07-22 | Ibio Inc. | Influenza hemagglutinin antibodies, compositions and related methods |
| US20110158982A1 (en) * | 2009-10-05 | 2011-06-30 | The Regents Of The University Of Michigan | COMPOSITIONS AND METHODS FOR INHIBITING MAdCAM |
| US10435458B2 (en) | 2010-03-04 | 2019-10-08 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variants with reduced Fcgammar binding |
| EP2552956A1 (en) * | 2010-03-26 | 2013-02-06 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies and uses thereof |
| AU2011305306C1 (en) | 2010-09-22 | 2016-02-18 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
| CN103298937B (zh) | 2010-11-17 | 2016-05-25 | 中外制药株式会社 | 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子 |
| CN102603649B (zh) * | 2011-01-20 | 2016-05-25 | 赣南师范学院 | 一种以地巴唑为先导分子的荧光探针化合物及其制备方法 |
| US20120189633A1 (en) | 2011-01-26 | 2012-07-26 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies and uses thereof |
| KR20230005405A (ko) | 2011-02-25 | 2023-01-09 | 추가이 세이야쿠 가부시키가이샤 | ＦｃγＲＩＩｂ 특이적 Ｆｃ 항체 |
| CN105968209B (zh) | 2011-04-19 | 2021-08-03 | 美国政府(由卫生和人类服务部的部长所代表) | 对磷脂酰肌醇蛋白聚糖3特异的人单克隆抗体及其用途 |
| MX362132B (es) | 2011-05-10 | 2019-01-07 | Nestec Sa | Metodos para perfilado de actividad de enfermedad para manejo de terapia personalizado. |
| JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| TW201326209A (zh) | 2011-09-30 | 2013-07-01 | Chugai Pharmaceutical Co Ltd | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| TWI593705B (zh) | 2011-12-28 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient |
| DK2877493T3 (en) | 2012-07-25 | 2018-06-14 | Celldex Therapeutics Inc | ANTI-KIT ANTIBODIES AND APPLICATIONS THEREOF |
| KR102274722B1 (ko) * | 2012-08-23 | 2021-07-09 | 어젠시스 인코포레이티드 | 158p1d7 단백질에 결합하는 항체 |
| US9273093B2 (en) * | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| WO2014144817A2 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Inhibitory polypeptides specific to wnt inhibitors |
| SI2968443T1 (sl) | 2013-03-15 | 2022-01-31 | Protagonist Therapeutics, Inc. | Analogi hepcidina in njihova uporaba |
| CN105517571A (zh) | 2013-06-24 | 2016-04-20 | 中外制药株式会社 | 含有人源化抗上皮调节蛋白抗体作为有效成分的腺癌以外的非小细胞肺癌的治疗药 |
| US10227370B2 (en) | 2013-08-02 | 2019-03-12 | California Institute Of Technology | Heparan sulfate/heparin mimetics with anti-chemokine and anti-inflammatory activity |
| US9770461B2 (en) | 2013-08-02 | 2017-09-26 | California Institute Of Technology | Tailored glycopolymers as anticoagulant heparin mimetics |
| EP3041863A4 (en) | 2013-09-05 | 2017-08-16 | Amgen Inc. | Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles |
| US10081681B2 (en) | 2013-09-20 | 2018-09-25 | Bristol-Myers Squibb Company | Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors |
| CN105764922B (zh) | 2013-09-27 | 2020-07-17 | 中外制药株式会社 | 多肽异源多聚体的制备方法 |
| KR102787208B1 (ko) | 2014-05-16 | 2025-03-27 | 프로타고니스트 테라퓨틱스, 인코포레이티드 | α4β7 인테그린 티오에테르 펩티드 길항제 |
| MX377275B (es) | 2014-05-16 | 2025-03-07 | Amgen Inc | Ensayo para detectar poblaciones celulares linfocitos t colaboradores 1 (th1) y linfocitos t colaboradores (th2). |
| CN113908269A (zh) | 2014-05-23 | 2022-01-11 | 塞尔德克斯医疗公司 | 嗜酸性粒细胞或肥大细胞相关病症的治疗 |
| CN107206254B (zh) | 2014-07-17 | 2021-08-24 | 领导医疗有限公司 | 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途 |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| US10301371B2 (en) | 2014-10-01 | 2019-05-28 | Protagonist Therapeutics, Inc. | Cyclic monomer and dimer peptides having integrin antagonist activity |
| US9809623B2 (en) | 2014-10-01 | 2017-11-07 | Protagonist Therapeutics, Inc. | α4β7 peptide monomer and dimer antagonists |
| US20170327584A1 (en) | 2014-11-26 | 2017-11-16 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the Treatment of Fistulizing Crohn's Disease |
| IL278014B2 (en) | 2014-12-19 | 2023-10-01 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use |
| JP6174782B2 (ja) | 2014-12-19 | 2017-08-02 | 中外製薬株式会社 | 抗ｃ５抗体および使用方法 |
| CA2916283C (en) * | 2015-01-09 | 2024-07-02 | Pfizer Inc. | MADCAM ANTAGONIST DOSING REGIMEN |
| CN107108729A (zh) | 2015-02-05 | 2017-08-29 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il‑8‑结合抗体，及其应用 |
| PT3258951T (pt) | 2015-02-19 | 2020-08-18 | Compugen Ltd | Anticorpos anti-pvrig e métodos de utilização |
| KR101892883B1 (ko) | 2015-02-27 | 2018-10-05 | 추가이 세이야쿠 가부시키가이샤 | Il-6 관련 질환 치료용 조성물 |
| US11142587B2 (en) | 2015-04-01 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide hetero-oligomer |
| US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE |
| US11649262B2 (en) | 2015-12-28 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
| US20190002503A1 (en) | 2015-12-30 | 2019-01-03 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| MX2018010988A (es) | 2016-03-14 | 2019-01-21 | Chugai Pharmaceutical Co Ltd | Farmaco terapeutico que induce lesion celular para usarse en terapia de cancer. |
| WO2017160700A1 (en) | 2016-03-14 | 2017-09-21 | Millennium Pharmaceuticals, Inc. | Methods of treating or preventing graft versus host disease |
| MX2018011169A (es) | 2016-03-14 | 2018-12-06 | Millennium Pharm Inc | Metodo para prevenir la enfermedad del injerto contra huesped. |
| CA3017926C (en) | 2016-03-23 | 2023-10-10 | Protagonist Therapeutics, Inc. | Methods for synthesizing .alpha.4.beta.7 peptide antagonists |
| JP7069032B2 (ja) | 2016-03-24 | 2022-05-17 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | がん免疫治療における胃腸の免疫関連有害事象の治療方法 |
| TW201735949A (zh) | 2016-03-24 | 2017-10-16 | 千禧製藥公司 | 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法 |
| MX2018012648A (es) | 2016-04-28 | 2019-01-30 | Chugai Pharmaceutical Co Ltd | Preparaciones que contienen anticuerpos. |
| TWI831965B (zh) | 2016-08-05 | 2024-02-11 | 日商中外製藥股份有限公司 | Il-8相關疾病之治療用或預防用組成物 |
| KR101877349B1 (ko) | 2016-08-05 | 2018-07-17 | 농업회사법인 주식회사 한라종합식품 | 황칠 구운 소금 제조방법 |
| EP4467565A3 (en) | 2016-12-21 | 2025-03-12 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| EP3596225A1 (en) | 2017-03-14 | 2020-01-22 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
| AU2018234810B2 (en) * | 2017-03-15 | 2023-05-11 | Pandion Operations, Inc. | Targeted immunotolerance |
| WO2018203545A1 (ja) | 2017-05-02 | 2018-11-08 | 国立研究開発法人国立精神・神経医療研究センター | Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法 |
| US10676516B2 (en) * | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| IL322104A (en) | 2017-05-30 | 2025-09-01 | Bristol Myers Squibb Co | Treatment of lag-3 positive tumors |
| WO2018222722A2 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody |
| AU2018277256A1 (en) | 2017-05-31 | 2020-01-30 | Prometheus Biosciences, Inc. | Methods for assessing mucosal healing in Crohn's disease patients |
| CU20200002A7 (es) | 2017-07-14 | 2020-11-30 | Pfizer | Anticuerpos contra madcam |
| EP3681900A4 (en) | 2017-09-11 | 2021-09-08 | Protagonist Therapeutics, Inc. | OPIOID AGONIST PEPTIDES AND THEIR USES |
| SG11202003833TA (en) | 2017-11-01 | 2020-05-28 | Chugai Pharmaceutical Co Ltd | Antibody variant and isoform with lowered biological activity |
| JP2021505156A (ja) * | 2017-12-06 | 2021-02-18 | パンディオン・オペレーションズ・インコーポレイテッド | 標的化免疫寛容 |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| JP7290645B2 (ja) | 2017-12-13 | 2023-06-13 | エックスディーシーエクスプローラー （シャンハイ） カンパニー リミテッド | ＥＧＦＲｖＩＩＩ抗体ならびにその複合体、製造方法および使用 |
| EP4501952A3 (en) | 2018-02-08 | 2025-04-16 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| CN111954719B (zh) | 2018-03-26 | 2025-07-18 | 美国安进公司 | 细胞培养物中产生的抗体的总去岩藻糖基化糖型 |
| EP3876986A4 (en) * | 2018-09-18 | 2022-06-01 | Pandion Operations, Inc. | Targeted immunotolerance |
| BR112021018156A2 (pt) * | 2019-03-20 | 2021-11-16 | Kindred Biosciences Inc | Antagonistas de ngf para uso médico |
| WO2020236875A1 (en) * | 2019-05-20 | 2020-11-26 | Pandion Therapeutics, Inc. | Madcam targeted immunotolerance |
| AU2020311395A1 (en) | 2019-07-10 | 2022-02-03 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| BR112022005583A2 (pt) | 2019-09-26 | 2022-09-20 | Amgen Inc | Métodos para a produção de composições de anticorpos |
| CN110887966B (zh) * | 2019-12-17 | 2021-02-12 | 丹娜(天津)生物科技股份有限公司 | 一种曲霉菌的化学发光检测试剂盒及其应用 |
| PL4090670T3 (pl) | 2020-01-15 | 2025-07-28 | Janssen Biotech, Inc | Peptydowe inhibitory receptora interleukiny-23 i ich zastosowanie w leczeniu chorób zapalnych |
| CA3168135A1 (en) | 2020-01-15 | 2021-07-22 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| US20230273126A1 (en) | 2020-06-04 | 2023-08-31 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
| CN111714781B (zh) * | 2020-06-24 | 2022-08-05 | 北京夏禾科技有限公司 | 一种牙齿美白组合及其使用方法 |
| AU2021360897A1 (en) | 2020-10-15 | 2023-05-25 | Amgen Inc. | Relative unpaired glycans in antibody production methods |
| WO2022109328A1 (en) | 2020-11-20 | 2022-05-27 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of interleukin-23 receptor |
| AU2022289365A1 (en) | 2021-06-07 | 2023-12-14 | Amgen Inc. | Using fucosidase to control afucosylation level of glycosylated proteins |
| KR20240032857A (ko) * | 2021-06-21 | 2024-03-12 | 인스티튜트 구스타브 루시 | 암- 또는 항생제-유도된 디스바이오시스를 진단하는 방법 및 면역요법에 의한 암 치료를 개선시키기 위한 그의 용도 |
| JP2024525732A (ja) | 2021-07-14 | 2024-07-12 | ヤンセン バイオテツク，インコーポレーテツド | インターロイキン－２３受容体の脂質化ペプチド阻害剤 |
| WO2023059607A1 (en) | 2021-10-05 | 2023-04-13 | Amgen Inc. | Fc-gamma receptor ii binding and glycan content |
| US12112433B2 (en) * | 2022-04-06 | 2024-10-08 | Qualcomm Incorporated | Apparatus and methods for image reconstruction using machine learning processes |
| WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| JP2025538586A (ja) | 2022-11-22 | 2025-11-28 | 武田薬品工業株式会社 | 非アルコール性脂肪性肝炎の治療のためのＭＡｄＣＡＭ－１抗体の投薬レジメン |
| WO2024220916A1 (en) | 2023-04-20 | 2024-10-24 | Amgen Inc. | Methods of determining relative unpaired glycan content |
| WO2025038600A1 (en) | 2023-08-14 | 2025-02-20 | Amgen Inc. | Methods for reducing yellow color |
| WO2025101820A1 (en) | 2023-11-08 | 2025-05-15 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) * | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) * | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4740461A (en) * | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US5168062A (en) * | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| JP2532858B2 (ja) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | 形質転換したミエロ―マ細胞系 |
| US4968615A (en) * | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4959455A (en) * | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) * | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| US5151540A (en) * | 1986-11-26 | 1992-09-29 | Hoechst Celanese Corporation | Thio carbamates and their derivatives |
| US5750172A (en) * | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) * | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) * | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5959177A (en) * | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US5633076A (en) * | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US6150584A (en) * | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) * | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69133566T2 (de) * | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US20040010810A1 (en) * | 1990-01-12 | 2004-01-15 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5151510A (en) * | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9014932D0 (en) * | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5165424A (en) | 1990-08-09 | 1992-11-24 | Silverman Harvey N | Method and system for whitening teeth |
| EP0546091B1 (en) * | 1990-08-29 | 2007-01-24 | Pharming Intellectual Property BV | Homologous recombination in mammalian cells |
| US5633425A (en) * | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5770429A (en) * | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) * | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5789650A (en) * | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) * | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) * | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5462990A (en) * | 1990-10-15 | 1995-10-31 | Board Of Regents, The University Of Texas System | Multifunctional organic polymers |
| DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
| DK1279731T3 (da) | 1991-03-01 | 2007-09-24 | Dyax Corp | Fremgangsmåde til udvikling af bindende miniproteiner |
| DK1471142T3 (da) | 1991-04-10 | 2009-03-09 | Scripps Research Inst | Heterodimere receptor-biblioteker under anvendelse af fagemider |
| CA2103059C (en) * | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| WO1993004169A1 (en) * | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| ATE181571T1 (de) | 1991-09-23 | 1999-07-15 | Medical Res Council | Methoden zur herstellung humanisierter antikörper |
| JPH05244982A (ja) * | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5777085A (en) * | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
| WO1993016043A1 (en) | 1992-02-18 | 1993-08-19 | Otsuka Kagaku Kabushiki Kaisha | β-LACTAM COMPOUND AND CEPHEM COMPOUND, AND PRODUCTION THEREOF |
| US5714350A (en) * | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
| WO1994013312A1 (en) | 1992-12-15 | 1994-06-23 | The Board Of Trustees Of The Leland Stanford Junior University | Mucosal vascular addressin, dna and expression |
| ES2146648T3 (es) | 1993-03-09 | 2000-08-16 | Genzyme Corp | Procedimiento de aislamiento de proteinas de la leche. |
| US5827690A (en) * | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5643763A (en) * | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
| US6046037A (en) * | 1994-12-30 | 2000-04-04 | Hiatt; Andrew C. | Method for producing immunoglobulins containing protection proteins in plants and their use |
| US7750137B2 (en) | 1995-09-01 | 2010-07-06 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressins |
| US7803904B2 (en) * | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
| DE69637155T2 (de) * | 1995-02-10 | 2008-02-07 | Millennium Pharmaceuticals, Inc., Cambridge | Addressine der schleimhaut und der blutgefässe und ihre verwendung |
| US6551593B1 (en) * | 1995-02-10 | 2003-04-22 | Millennium Pharmaceuticals, Inc. | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam |
| US6130364A (en) * | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US6091001A (en) * | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| KR100479146B1 (ko) * | 1995-04-21 | 2005-05-16 | 셀 제네시스, 인코포레이티드 | 큰게놈dna결실유발법 |
| ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0773288A3 (en) | 1995-08-29 | 1997-07-09 | Kirin Brewery | Chimera animal and its method of manufacture |
| US6037324A (en) | 1996-01-04 | 2000-03-14 | Leukosite, Inc. | Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor |
| US5714352A (en) * | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| US5994619A (en) * | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| US5916771A (en) * | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| WO1999045031A2 (en) | 1998-03-03 | 1999-09-10 | Abgenix, Inc. | Cd147 binding molecules as therapeutics |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| US7090845B2 (en) * | 1998-05-13 | 2006-08-15 | Genentech, Inc. | Diagnosis and treatment of hepatic disorders |
| IL139129A0 (en) * | 1998-05-13 | 2001-11-25 | Genentech Inc | Diagnosis and treatment of hepatic disorders |
| WO2000009560A2 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| ES2706547T3 (es) | 1998-12-23 | 2019-03-29 | Pfizer | Anticuerpos monoclonales humanos para CTLA-4 |
| WO2001018176A1 (en) | 1999-09-03 | 2001-03-15 | Human Genome Sciences, Inc. | Immunoglobulin superfamily polynucleotides, polypeptides, and antibodies |
| US6517529B1 (en) * | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
| US20010046496A1 (en) * | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
| JP2003089656A (ja) * | 2001-09-19 | 2003-03-28 | Nippon Kayaku Co Ltd | 移植による免疫反応抑制剤 |
| CA2466034C (en) | 2001-11-08 | 2012-12-18 | Protein Design Labs, Inc. | Stable aqueous pharmaceutical formulations of daclizumab antibodies |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| WO2003072040A2 (en) | 2002-02-25 | 2003-09-04 | Elan Pharmaceuticals, Inc. | Administration of agents for the treatment of inflammation |
| WO2004081049A1 (en) * | 2003-03-10 | 2004-09-23 | Auckland Uniservices Limited | Monoclonal antibodies that recognise mucosal addressin cell adhesion molecule-1 (madcam-1), soluble madcam-1 and uses thereof |
| BRPI0403964B8 (pt) | 2003-04-04 | 2021-05-25 | Genentech Inc | formulações líquidas estáveis, artigo manufaturado e uso dessas formulações para o tratamento de disfunção mediada por ige |
| PL2177537T3 (pl) | 2004-01-09 | 2012-06-29 | Pfizer | Przeciwciała przeciw MadCAM |
| EP1718310A4 (en) | 2004-02-06 | 2009-05-06 | Elan Pharm Inc | METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE |
| AR054233A1 (es) | 2005-03-08 | 2007-06-13 | Pharmacia & Upjohn Co Llc | Composiciones de anticuerpos igg2 |
| BRPI0612645A2 (pt) | 2005-07-08 | 2010-11-23 | Pfizer Ltd | uso de anticorpos anti-madcam para o tratamento de doença celìaca e espru tropical |
| DE602006017373D1 (de) | 2005-07-08 | 2010-11-18 | Pfizer Ltd | Madcam-antikörper |
| CA2614622A1 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | New combination of anti-madcam antibody and antifibrotic caspase inhibitor to treat liver fibrosis |
| WO2007007160A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat fever |
| WO2007007151A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Use of anti-mad-cam antibody for the treatment of emphysema |
| WO2007007152A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat metastatic cancers and chloroma |
| WO2007007159A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat uterine disorders |
-
2005
- 2005-01-07 PL PL10150359T patent/PL2177537T3/pl unknown
- 2005-01-07 KR KR1020127004435A patent/KR20120048644A/ko not_active Ceased
- 2005-01-07 CN CN2005800021223A patent/CN1956738B/zh not_active Expired - Lifetime
- 2005-01-07 TW TW101100882A patent/TWI366570B/zh not_active IP Right Cessation
- 2005-01-07 EA EA200601297A patent/EA012872B1/ru not_active IP Right Cessation
- 2005-01-07 ZA ZA200605825A patent/ZA200605825B/en unknown
- 2005-01-07 TW TW094100530A patent/TWI363762B/zh not_active IP Right Cessation
- 2005-01-07 MY MYPI20050059A patent/MY140862A/en unknown
- 2005-01-07 MX MXPA06007843A patent/MXPA06007843A/es active IP Right Grant
- 2005-01-07 AR ARP050100053A patent/AR047372A1/es active IP Right Grant
- 2005-01-07 US US11/031,485 patent/US9328169B2/en active Active
- 2005-01-07 AP AP2006003689A patent/AP2006003689A0/xx unknown
- 2005-01-07 MX MX2014007315A patent/MX350383B/es unknown
- 2005-01-07 CA CA2552523A patent/CA2552523C/en not_active Expired - Lifetime
- 2005-01-07 PT PT10150359T patent/PT2177537E/pt unknown
- 2005-01-07 WO PCT/US2005/000370 patent/WO2005067620A2/en not_active Ceased
- 2005-01-07 ES ES05711290T patent/ES2362667T3/es not_active Expired - Lifetime
- 2005-01-07 DO DO2005000002A patent/DOP2005000002A/es unknown
- 2005-01-07 AT AT05711290T patent/ATE501174T1/de not_active IP Right Cessation
- 2005-01-07 AU AU2005204678A patent/AU2005204678B2/en not_active Expired
- 2005-01-07 DE DE602005026779T patent/DE602005026779D1/de not_active Expired - Lifetime
- 2005-01-07 PA PA20058621301A patent/PA8621301A1/es unknown
- 2005-01-07 BR BRPI0506768-5A patent/BRPI0506768B1/pt not_active IP Right Cessation
- 2005-01-07 NZ NZ548702A patent/NZ548702A/en not_active IP Right Cessation
- 2005-01-07 NL NL1027975A patent/NL1027975C2/nl not_active IP Right Cessation
- 2005-01-07 ES ES10150359T patent/ES2372733T3/es not_active Expired - Lifetime
- 2005-01-07 EP EP10150359A patent/EP2177537B1/en not_active Expired - Lifetime
- 2005-01-07 SV SV2005001990A patent/SV2006001990A/es not_active Application Discontinuation
- 2005-01-07 SI SI200531421T patent/SI2177537T1/sl unknown
- 2005-01-07 MX MX2017011253A patent/MX370489B/es unknown
- 2005-01-07 OA OA1200600223A patent/OA13358A/en unknown
- 2005-01-07 PE PE2005000045A patent/PE20051053A1/es active IP Right Grant
- 2005-01-07 EP EP05711290A patent/EP1709080B1/en not_active Expired - Lifetime
- 2005-01-07 UY UY28716A patent/UY28716A1/es unknown
- 2005-01-07 JP JP2006549399A patent/JP4315982B2/ja not_active Expired - Lifetime
- 2005-01-07 AT AT10150359T patent/ATE522547T1/de active
- 2005-01-07 DK DK10150359.7T patent/DK2177537T3/da active
- 2005-01-07 BR BR122021007893-9A patent/BR122021007893B1/pt active IP Right Grant
-
2006
- 2006-06-26 CR CR8485A patent/CR8485A/es not_active Application Discontinuation
- 2006-07-07 MX MX2019015195A patent/MX2019015195A/es unknown
- 2006-07-07 TN TNP2006000216A patent/TNSN06216A1/en unknown
- 2006-07-09 IL IL176749A patent/IL176749A0/en active IP Right Grant
- 2006-07-10 US US11/484,247 patent/US7932372B2/en not_active Ceased
- 2006-07-31 EC EC2006006741A patent/ECSP066741A/es unknown
- 2006-08-03 MA MA29232A patent/MA28430B1/fr unknown
- 2006-08-08 NO NO20063601A patent/NO342054B1/no unknown
- 2006-08-09 KR KR1020067016064A patent/KR101262032B1/ko not_active Expired - Lifetime
-
2007
- 2007-08-20 US US11/894,559 patent/US20080124339A1/en not_active Abandoned
-
2008
- 2008-06-06 JP JP2008149091A patent/JP4729076B2/ja not_active Expired - Lifetime
-
2009
- 2009-11-16 JP JP2009260786A patent/JP5094818B2/ja not_active Expired - Lifetime
-
2012
- 2012-07-10 JP JP2012154794A patent/JP5836896B2/ja not_active Expired - Lifetime
-
2014
- 2014-03-19 US US14/219,900 patent/USRE45847E1/en active Active
-
2015
- 2015-07-10 JP JP2015138764A patent/JP6215875B2/ja not_active Expired - Lifetime
-
2016
- 2016-03-31 US US15/086,930 patent/US10259872B2/en not_active Expired - Lifetime
-
2017
- 2017-01-16 JP JP2017004899A patent/JP6423024B2/ja not_active Expired - Lifetime
-
2018
- 2018-05-01 JP JP2018087973A patent/JP6637104B2/ja not_active Expired - Lifetime
-
2019
- 2019-02-21 US US16/282,157 patent/US20190300605A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009005695A5 (cg-RX-API-DMAC7.html) | ||
| JP2010042025A5 (cg-RX-API-DMAC7.html) | ||
| CA2861793C (en) | Method of providing monoclonal auto-antibodies with desired specificity | |
| AU2008320987B2 (en) | Humanized antibodies against TL1A | |
| CN112262156B (zh) | 抗her2抗体 | |
| US10875916B2 (en) | Nucleic acid molecules encoding monoclonal antibodies specific for IL-17F | |
| JP2014534218A5 (cg-RX-API-DMAC7.html) | ||
| JP2022022994A (ja) | Ｔｌ１ａ抗体で炎症性腸疾患を処置する方法 | |
| JP2020535799A5 (cg-RX-API-DMAC7.html) | ||
| RU2014120755A (ru) | Иммуносвязующие агенты, направленные против tnf | |
| CN112513090A (zh) | 结合人il-4r的抗体、其抗原结合片段及其医药用途 | |
| JP2012501670A5 (cg-RX-API-DMAC7.html) | ||
| CA2822288A1 (en) | Anti-c5/c5a/c5adesr antibodies and fragments | |
| JP6799076B2 (ja) | インターフェロンベータ抗体およびその使用 | |
| HK1219512A1 (zh) | 用於诊断和治疗炎性肠病的方法 | |
| TW201127401A (en) | Compositions and methods for treating inflammatory disorders | |
| JP2023540444A (ja) | 治療用抗体 | |
| JP2025169256A (ja) | α４β７阻害薬及びＩＬ－２３阻害薬の併用療法 | |
| JP2012505227A5 (cg-RX-API-DMAC7.html) | ||
| IL301887A (en) | True human antibody specific for interleukin 1 alpha | |
| US20230357391A1 (en) | Cd47 binding agents and uses thereof | |
| WO2022076634A1 (en) | Methods and agents for treating, preventing, diagnosing, and evaluating therapy for fibrotic, autoimmune, and inflammatory conditions | |
| JP2020533953A5 (cg-RX-API-DMAC7.html) | ||
| US20220267428A1 (en) | BLOCKADE OF RGMb FOR TREATING INFLAMMATORY BOWEL DISEASE AND COLITIS | |
| JPWO2021188851A5 (cg-RX-API-DMAC7.html) |